

## Editorial

# Secondary Osteoporosis: Endocrine and Metabolic Causes of Bone Mass Deterioration

**Tomasz Miazgowski,<sup>1</sup> Michael Kleerekoper,<sup>2</sup> Dieter Felsenberg,<sup>3</sup>  
Jan J. Štěpán,<sup>4</sup> and Paweł Szulc<sup>5</sup>**

<sup>1</sup>Department of Hypertension and Internal Medicine, Pomeranian Medical University, Szczecin, Poland

<sup>2</sup>Wayne State University, St. John River District Hospital, MI 48054, USA

<sup>3</sup>Klinik und Poliklinik für Radiologie und Nuklearmedizin, Zentrum für Muskel- und Knochenforschung, Berlin, Germany

<sup>4</sup>Charles University, Prague, Czech Republic

<sup>5</sup>INSERM Unit 821, Lyon, France

Correspondence should be addressed to Tomasz Miazgowski, miazgowski@interia.pl

Received 29 December 2011; Accepted 29 December 2011

Copyright © 2012 Tomasz Miazgowski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Secondary osteoporosis results from medical conditions or treatments that interfere with the attainment of peak bone mass and/or may predispose to accelerated bone loss. Although secondary osteoporosis is less common, it is becoming more frequently diagnosed. Apart from the well-defined risk of secondary osteoporosis in patients requiring long-term corticosteroids therapy, an increasing list of dietary, lifestyle, endocrine, metabolic, and other causes of bone mass deterioration has been identified (Table 1). Recently it has been demonstrated that, in contrast to primary osteoporosis which is associated with age, gender, and family history, secondary osteoporosis shows a prevalence in men similar to that in women (men 21% versus women 17.5%) [1]. However, at presentation with a recent clinical vertebral or nonvertebral fracture, at least 27% of patients have previously unknown contributors to secondary osteoporosis, which are treatable or need follow-up [2]. Therefore, a careful medical examination always should be carried out in each patient with a recent fracture to exclude potentially reversible causes of bone loss. In comparison with primary osteoporosis, treatment of secondary osteoporosis is usually more complex and requires treating the underlying disease.

The main focus of this special issue is on current research that advances our understanding of the mechanisms underlying the endocrine and metabolic causes of bone mass deterioration. In the paper “*Bone mineral density accrual determines energy expenditure with refeeding in anorexia nervosa and supersedes return of menses,*” the authors in

the clinical study examined the disproportionate increase in resting energy expenditure that occurs with refeeding of women with anorexia nervosa to determine if it was related to bone mass increase. They found that prolonged nutritional rehabilitation may lead to recovery from osteopenia (a common finding in anorexia nervosa) and resumption of menses in the women who remain amenorrheic with low bone mineral density (BMD). The paper entitled “*Protective role of black tea extract (BTE) against non-alcoholic steatohepatitis (NASH)-induced skeletal dysfunction*” was aimed to examine the chemoprotective actions of aqueous BTE on decreased BMD induced by nonalcoholic steatohepatitis in the Wistar rats. Some previous studies have suggested that habitual tea consumption might have beneficial effect on BMD in adults. In this study, the authors confirmed this suggestion in rats and also found that BTE may influence levels of RANKL, osteoprotegerin, and bone turnover markers. The paper “*Bone health in patients with multiple sclerosis*” describes the up-to-date diagnostic criteria and includes detailed review of the common risk factors, pathophysiology, and treatment options of secondary osteoporosis in patients with multiple sclerosis. The paper “*A roadmap to the brittle bones of cystic fibrosis*” summarizes the current knowledge on the risk for osteoporosis in this autosomal recessive disorder. Unlike primary osteoporosis, bone disease in cystic fibrosis begins at a young age and is associated with significant morbidity due to fractures and decreased lung function. This paper reviews the pathophysiology, current clinical practice

TABLE 1: Causes of secondary osteoporosis.

<i>Dietary</i>	
Anorexia nervosa	
Excessive protein intake	
Excess vitamin A	
Inadequate vitamin D intake	
Smoking	
Excess alcohol intake	
Parenteral nutrition	
<i>Lifestyle</i>	
Low physical activity	
Prolonged immobilization	
<i>Endocrine</i>	
Adrenal insufficiency	
Cushing's syndrome	
Diabetes mellitus	
Hyperthyroidism	
Hypogonadism	
Hypopituitarism	
Pregnancy	
<i>Metabolic</i>	
Malabsorption syndrome	
Chronic metabolic acidosis	
<i>Systematic diseases</i>	
End-stage renal disease	
Primary biliary cirrhosis	
Inflammatory bowel disease	
Cystic fibrosis	
Rheumatoid arthritis	
Chronic obstructive pulmonary disease	
Mastocytosis	
Chronic inflammation	
<i>Surgery/transplantation</i>	
Bariatric surgery	
Organ transplantation	
<i>Medications</i>	
Corticosteroids	
Antiepileptics	
Selective serotonin-reuptake inhibitors	
Heparin	

guidelines, and future therapies for treating bone disease associated with cystic fibrosis. Another paper in this issue, "Are selective serotonin reuptake inhibitors a secondary cause of decreased bone density?", deals with severe complication of therapy with commonly prescribed selective serotonin-reuptake inhibitors (SSRIs). Although multiple consistent findings reveal a trend suggesting that SSRI use may negatively impact bone and result in lower BMD, a definitive causal relationship cannot be drawn. However, a growing body of evidence suggests an association between SSRI use

and bone loss which seems sufficient to consider adding SSRIs to the list of medications that contribute to secondary osteoporosis. Another review paper in this issue, "Secondary osteoporosis in patients with juvenile idiopathic arthritis," focuses on focal and systemic bone loss seen in juvenile idiopathic osteoporosis. Several clinical and epidemiological studies are reviewed in order to highlight putative factors that may contribute to bone loss in juvenile idiopathic osteoporosis, including low lean mass, growth retardation, impact of proinflammatory cytokines on bone remodeling, RANK/RANKL/osteoprotegerin imbalance, and abnormal Wnt signaling.

The papers presented in this special issue depict some novel and hitherto not intensively studied aspects of secondary osteoporosis, underscoring the complexity of mechanisms that predispose to bone mass deterioration induced by metabolic and endocrine risk factors. The editors thank the authors of all submissions and hope that the content of this special issue will be useful for clinical practice and future research.

Tomasz Miazgowski

Michael Kleerekoper


Dieter Felsenberg

Jan J. Štěpán

Paweł Szulc

## References

- [1] E. Romagnoli, R. Del Fiacco, S. Russo et al., "Secondary osteoporosis in men and women: clinical challenge of an unresolved issue," *Journal of Rheumatology*, vol. 38, no. 8, pp. 1671–1679, 2011.
- [2] S. P. G. Bours, T. A. C. M. van Geel, P. P. M. M. Geusens et al., "Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture," *Journal of Clinical Endocrinology and Metabolism*, vol. 96, no. 5, pp. 1360–1367, 2011.



**Hindawi**  
Submit your manuscripts at  
<http://www.hindawi.com>

